Fig. 2

LncROPM is an oncogene and correlated with clinical characteristics as well as stemness in patients with breast cancer. A The expression of lncROPM in patients who died of breast cancer (n = 120) and surviving from it (n = 705) was analyzed using the TCGA-BRCA database (RNAseq data). B, C Kaplan–Meier survival curve to assess 3-year disease-free survival (B) and progression-free survival (C) in breast cancer patients with high or low lncROPM expression based on TCGA-BRCA database. D, E Kaplan–Meier survival analysis of disease-free survival (D) and progression-free survival (E) according to the lncROPM expression levels in ER⁻PR⁻Her2⁻ breast cancer patients who received clinic treatment based on TCGA-BRCA database. F qRT-PCR analysis of lncROPM expression in 50 paired breast cancer tissues and adjacent normal tissues. G Representative RNA-FISH staining of lncROPM in breast cancer tissues. The nuclei were stained with DAPI. Fluorescent staining: DAPI (blue), lncROPM (red). H, I Pearson analysis for the correlation between lncROPM and SOX2 expression levels (H) or OCT4 expression levels (I) in 130 breast cancer tissues. J qRT-PCR analysis of lncROPM expression in non-BCSCs and BCSCs from different breast tumor grade samples. K qRT-PCR analysis of lncROPM expression in breast cancer chemosensitive tissues (n = 30) and chemoresistant tissues (n = 30) (left panel). Representative RNA-FISH staining of lncROPM in tissues was shown in the right panel. The data are presented as the mean ± SD, *p < 0.05, **p < 0.01